Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RGNXBullishIndustry Newsnews

High materiality7/10

REGENXBIO reports three-year NPDR data boosting sura-vec one-time therapy potential

Sep 24, 2026, 7:29 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Durable 3-year efficacy with a one-time in-office approach and a solid AbbVie collaboration could drive multiple-year upside, though no FDA approval yet; positive data often re-rates biotech valuations when coupled with a clear near-term trial catalyst.

AI summary

What happened, with direct paths to the underlying reporting

REGENXBIO reported three-year ALTITUDE data for surabgene lomparvovec (sura-vec) in NPDR. Among Dose Level 3 participants, 60% achieved >2-step DRSS with no additional DR treatment and no vision-threatening events over three years, with no new safety signals. The results support a potential one-time in-office therapy in collaboration with AbbVie, with NAAVIGATE readouts as a near- to mid-term catalyst.

REGENXBIO reports three-year ALTITUDE NPDR data for sura-vec (ABBV-RGX-314).
60% (6/10) DL3 NPDR patients achieved >2-step DRSS at year 3.
No vision-threatening events or intraocular inflammation over 3 years.
Dose Level 3 is being evaluated in NAAVIGATE Phase IIb/III for NPDR.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

REGENXBIO reports three-year NPDR data boosting sura-vec one-time therapy potential

FDA clinical hold on Regenxbio's Hunter syndrome therapy raises near-term risk

REGENXBIO's sura-vec shows durable 5-year efficacy; topline data due in 2026

FDA Expedited Review for RGX-121 CAMPSITE Data, BLA Resubmission Planned

FDA reversal on Regenxbio therapy could unlock regulatory approval opportunity